Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-09 pm EDT			5-day change	1st Jan Change
55.74 ^USD	+6.13%		+5.48%	+89.01%

Mar. 05	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
Mar. 04	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE

Sector Update: Health Care Stocks Mixed Late Afternoon

Published on 02/10/2026 at 03:44 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Moderna, Inc.

Mar. 05	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
Mar. 04	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE
Mar. 04	Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup	DJ
Mar. 04	Equities Rise on Upbeat Data as Markets Look Past Middle East Conflict	MT
Mar. 04	US Equity Markets End Higher After Strong Services, Jobs Data	MT
Mar. 04	Moderna Shares Rise After Company Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT
Mar. 04	Equities Rise Intraday as Markets Parse Macro Data Amid Middle East Conflict	MT
Mar. 04	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE
Mar. 04	Wall Street mixed as oil retreat eases inflation fears
Mar. 04	Top Midday Stories: Bessent Says US to Fortify Gulf Oil Trade, 15% Tariff Rolling Out This Week; CrowdStrike Fiscal Q4 Adjusted Earnings, Revenue Increase	MT
Mar. 04	Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang	RE
Mar. 04	Global markets live: Goldman Sachs, Meta, Intel, Moderna, Adidas…
Mar. 04	Moderna to pay $950m to end litigation
Mar. 04	Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang	RE
Mar. 03	Moderna Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

4,700

Sector

Pharmaceuticals

More about the company